Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778298 | 0.85 | KMT2A (0.54) | L3MBTL1GSK3BNPC1RAB9AMAPT | |
| SCHEMBL19642535 | 0.84 | GSK3B (0.65) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8038291 | 0.84 | KMT2A (0.59) | L3MBTL1GSK3BNPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL27416693 | 0.82 | KMO (0.55) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL27416694 | 0.82 | KMO (0.55) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1376745 | 0.81 | L3MBTL1 (0.58) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10780575 | 0.81 | L3MBTL1 (0.58) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL28047842 | 0.81 | HDAC3 (0.59) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7797596 | 0.80 | L3MBTL1 (0.56) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7802060 | 0.80 | L3MBTL1 (0.56) | L3MBTL1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2502918-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8247414-B2 | Pyridizinone derivatives and the use thereof as H3 inhibitors | CEPHALON, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110288075-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | L3MBTL1 4806/4885HDAC3 24/4885HDAC4 39/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | L3MBTL1 3735/4885HDAC3 484/4885HDAC4 211/4885 |
| US-20110288075-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | L3MBTL1 3486/4885HDAC3 411/4885HDAC4 177/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | L3MBTL1 3510/4885HDAC3 368/4885HDAC4 175/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | L3MBTL1 3735/4885HDAC3 484/4885HDAC4 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.